Edgar Engleman - Nov 21, 2023 Form 4 Insider Report for Bolt Biotherapeutics, Inc. (BOLT)

Role
Director
Signature
/s/ William P. Quinn, Attorney-in-Fact
Stock symbol
BOLT
Transactions as of
Nov 21, 2023
Transactions value $
-$1,751
Form type
4
Date filed
11/22/2023, 07:45 PM
Previous filing
Nov 20, 2023
Next filing
Dec 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BOLT Common Stock Sale -$1.54K -1.71K -0.09% $0.90 1.95M Nov 21, 2023 By Vivo Capital Fund VIII, L.P. F1, F2
transaction BOLT Common Stock Sale -$213 -236 -0.09% $0.90 270K Nov 21, 2023 By Vivo Capital Surplus Fund VIII, L.P. F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.90 to $0.903, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4.
F2 The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.
F3 The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.